Patents by Inventor Michael A. Kinch

Michael A. Kinch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090186041
    Abstract: The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.
    Type: Application
    Filed: April 18, 2008
    Publication date: July 23, 2009
    Applicant: Functional Genetics, Inc.
    Inventors: LIMIN LI, Michael Kinch, Michael Goldbiatt
  • Publication number: 20090170890
    Abstract: A method of inhibiting viral infection in a mammal in need of same, includes administering an effective amount of at least one of the compounds of FGI-103 which are represented by 273, 365 and 510 either prophylactically to prevent viral infection, or therapeutically following viral infection. These compounds appear to selectively inhibit Caspase 8 as a method of preventing infective viral particle release. They can be administered IV, IP, orally or via other conventional administration routes. The compounds are highly effective, requiring relatively low dosages on the order of 1 ng/kg-200 mg/kg of body weight.
    Type: Application
    Filed: October 23, 2008
    Publication date: July 2, 2009
    Applicant: FUNCTIONAL GENETICS, INC.
    Inventors: Michael Kinch, Michael Goldblatt
  • Patent number: 7504672
    Abstract: A photodiode for detection of preferably infrared radiation wherein photons are absorbed in one region and detected in another. In one example embodiment, an absorbing P region is abutted with an N region of lower doping such that the depletion region is substantially (preferably completely) confined to the N region. The N region is also chosen with a larger bandgap than the P region, with compositional grading of a region of the N region near the P region. This compositional grading mitigates the barrier between the respective bandgaps. Under reverse bias, the barrier is substantially reduced or disappears, allowing charge carriers to move from the absorbing P region into the N region (and beyond) where they are detected. The N region bandgap is chosen to be large enough that the dark current is limited by thermal generation from the field-free p-type absorbing volume, and also large enough to eliminate tunnel currents in the wide gap region of the diode.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: March 17, 2009
    Assignee: DRS Sensors & Targeting Systems, Inc.
    Inventor: Michael A. Kinch
  • Patent number: 7459730
    Abstract: A photodiode for detection of preferably very long wavelength infrared radiation wherein low energy photons are absorbed in one region and detected in another. In one example embodiment, an absorbing P region is abutted with an N region of lower doping such that the depletion region is substantially (preferably completely) confined to the N region. The N region is also chosen with a larger bandgap than the P region, with compositional grading of a region of the N region near the P region. This compositional grading mitigates the barrier between the respective bandgaps. Under reverse bias, the barrier is substantially reduced or disappears, allowing charge carriers to move from the absorbing P region into the N region (and beyond) where they are detected. The N region bandgap is chosen to be large enough that the dark current is limited by thermal generation from the field-free p-type absorbing volume, and also large enough to eliminate tunnel currents in the wide bandgap region of the diode.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: December 2, 2008
    Assignee: DRS Sensors & Targeting Systems, Inc.
    Inventor: Michael A. Kinch
  • Publication number: 20080187528
    Abstract: The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.
    Type: Application
    Filed: November 15, 2007
    Publication date: August 7, 2008
    Applicant: Functional Genetics, Inc.
    Inventors: Limin Li, Michael Kinch, Michael Goldblatt
  • Publication number: 20080149808
    Abstract: A building structure formed of concrete and including dams to form raised structures on the roof and a method of overturning the concrete mold.
    Type: Application
    Filed: December 20, 2006
    Publication date: June 26, 2008
    Applicant: CANADIAN ROCKPORT HOMES LTD.
    Inventors: William Raymond MALONE, Chris Michael KINCH, Kenneth Oscar OLSEN, Herman Pablo ROSEN SAGREDO
  • Publication number: 20080124341
    Abstract: The invention provides for inhibition of viral disease by the provision to a mammalian host of antibodies directed against an escort protein likeTsg 101. These proteins appear on the surface of a cell, and thus can be bound by circulating antibodies thereto. By binding escort proteins on the cell surface, budding of viral particles is inhibited. The virus infects the initial cells, but cannot escape that cell to infect the body en masse.
    Type: Application
    Filed: November 13, 2007
    Publication date: May 29, 2008
    Applicant: Functional Genetics, Inc.
    Inventors: Roxanne Duan, Michael Kinch, Michael Goldblatt
  • Publication number: 20080089931
    Abstract: The present invention relates to methods and compositions designed for treatment, management, or prevention of a hyperproliferative cell disease, particular cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing low molecular weight protein tyrosine kinase (“LMW-PTP”) in particular using moieties that bind an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, and inhibits or reduces LMW-PTP expression and/or activity. In one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more agents that inhibit LMW-PTP expression and/or activity operatively associated with the delivery vehicle.
    Type: Application
    Filed: December 10, 2007
    Publication date: April 17, 2008
    Applicant: MedImmune, Inc.
    Inventor: Michael Kinch
  • Publication number: 20080044413
    Abstract: The present invention relates to bispecific single chain antibodies comprising a first binding domain that immunospecifically binds to the T-cell antigen CD3 and a second binding domain that immunospecifically binds to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term “EphA2-BiTEs.” The present invention further relates to methods and compositions designed for the treatment, prevention and/or management of disorders associated with aberrant expression and/or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancer hyperproliferative cell disorders, and infections. The invention further relates to vectors comprising polynucleotides encoding the EphA2-BiTEs of the invention, host cells transformed therewith, and their use in the production of said EphA2-BiTEs.
    Type: Application
    Filed: December 21, 2006
    Publication date: February 21, 2008
    Inventors: Scott Hammond, Peter Kiener, Elizabeth Bruckheimer, Michael Kinch, Shannon Roff, Ralf Lutterbuese, Petra Lutterbuese, Bernd Schlereth, Patrick Baeuerle, Peter Kufer
  • Publication number: 20080003210
    Abstract: The present invention relates to novel non-human primate receptor tyrosine kinases. In particular, the present invention relates to Rhesus EphA2 and Cynomolgus EphA2 nucleotide and amino acid sequences.
    Type: Application
    Filed: March 12, 2007
    Publication date: January 3, 2008
    Applicant: MedImmune, Inc.
    Inventors: Elizabeeth Bruckheimer, William Walsh, Michael Kinch
  • Publication number: 20070166314
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low Koff, thereby, inhibiting tumor cell growth and/or metastasis.
    Type: Application
    Filed: March 12, 2007
    Publication date: July 19, 2007
    Inventors: Michael Kinch, Kelly Carles-Kinch, Peter Kiener, Solomon Langermann
  • Publication number: 20070161064
    Abstract: Method and kits are provided for the detection and diagnosis of metastatic disease. More particularly, the methods and kits employ compounds that can detect EphA2, a specific epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. In one embodiment the compound is an antibody capable of binding to an epitope of EphA2.
    Type: Application
    Filed: March 12, 2007
    Publication date: July 12, 2007
    Applicant: Purdue Research Foundation
    Inventors: Michael Kinch, Nicole Zantek
  • Publication number: 20070134254
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: January 5, 2007
    Publication date: June 14, 2007
    Inventors: Michael Kinch, Kelly Carles-Kinch, Jane Stewart
  • Publication number: 20070086943
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: October 6, 2006
    Publication date: April 19, 2007
    Inventors: Michael Kinch, Kelly Carles-Kinch, Jane Stewart
  • Publication number: 20070065887
    Abstract: The present invention relates to methods and compositions designed for the treatment or management of pre-cancerous conditions, especially in order to prevent, delay, or decrease the likelihood that the pre-cancerous condition will progress to malignant cancer. The methods of the invention comprise the administration of an effective amount of one or more agents that decrease/inhibit PCDGF expression, secretion, and/or activity. The invention also provides pharmaceutical compositions comprising one or more PCDGF agents. In some embodiments, the PCDGF agents can be administered with other therapeutic agents for treatment or management of a pre-cancerous condition that are not PCDGF-based. Diagnostic methods and methods for screening for therapeutically useful PCDGF agents are also provided.
    Type: Application
    Filed: July 16, 2004
    Publication date: March 22, 2007
    Inventor: Michael Kinch
  • Publication number: 20070029485
    Abstract: An avalanche photodiode is operated in avalanche mode at a selected reverse bias that achieves high gain and a reduced gain normalized dark current.
    Type: Application
    Filed: August 3, 2005
    Publication date: February 8, 2007
    Inventors: Jeffrey Beck, Pradip Mitra, Chang-Feng Wan, Michael Kinch
  • Publication number: 20060121043
    Abstract: The present invention provides methods and compositions designed for the treatment, management, and/or amelioration of an infection, in particular an intracellular pathogen infection, such as a viral, bacterial, protozoa or fungal infection. In particular, the present invention provides methods for treating, managing, preventing and/or ameliorating an infection where the expression of EphA2 is upregulated in infected cells (e.g., infected epithelial cells), said methods comprising administering to a subject an effective amount of one or more EphA2/EphrinA1 Modulators. In accordance with the present invention, such methods may also comprise the administration of one or more therapies other than an EphA2/EphrinA1 Modulator.
    Type: Application
    Filed: October 27, 2005
    Publication date: June 8, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: Michael Kinch, Kelly Carles-Kinch
  • Publication number: 20060121042
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of various disorders associated with aberrant expression and/or activity of one or more Eph receptor tyrosine kinase family members and/or one or more Eph receptor ligands, particularly the Ephrins. In particular, the invention provides methods for the treatment, management, prevention and/or amelioration of a disorder associated with aberrant expression and/or activity(ies) of one or more Eph receptors and/or one or more Ephrins, the method comprising administering to a subject in need thereof an effective amount of one or more Eph/Ephrin Modulators. The present invention further relates to methods of modulating antibody specificity by tailoring the affinity to cognate antigens.
    Type: Application
    Filed: October 27, 2005
    Publication date: June 8, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: William Dall'Acqua, Melissa Damschroder, Michael Kinch, Kelly Carles-Kinch
  • Publication number: 20060122138
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of non-neoplastic hyperproliferative epithelial and/or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and/or aberrant angiogenesis. Non-limiting examples of such disorders include cirrhosis, fibrosis (e.g.
    Type: Application
    Filed: October 27, 2005
    Publication date: June 8, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: Michael Kinch, Kelly Carles-Kinch
  • Publication number: 20060093608
    Abstract: Low molecular weight protein tyrosine phosphatase (LMW-PTP) is identified as a novel diagnostic and therapeutic target in cancer diagnosis, prognosis and treatment. The invention provides diagnostic and treatment methods useful in connection with cancers expressing LMW-PTP and, optionally, EphA2 receptor. Also provided is a screening method that utilizes changes in the amount and/or activity of LMW-PTP to identify candidate cancer therapeutic agents that effectively target the oncoprotein EphA2.
    Type: Application
    Filed: May 22, 2003
    Publication date: May 4, 2006
    Inventor: Michael Kinch